Trial ID or NCT#

NCT04045665

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.

Official Title

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Jack Boyd
Jack Boyd
Cardiac surgeon, Cardiothoracic surgeon, Heart transplant surgeon, Heart and lung transplant surgeon, Vascular surgeon, Cardiovascular surgeon, Lung transplant surgeon
Clinical Associate Professor, Cardiothoracic Surgery
Joseph Woo
Joseph Woo
Cardiovascular surgeon, Cardiothoracic surgeon, Lung transplant surgeon
Norman E. Shumway Professor, Professor of Cardiothoracic Surgery and, by courtesy, of Bioengineering

Contact us to find out if this trial is right for you.

CONTACT

Nicholas Vesom